SKLB-646

N/A

Report date: 2022/05/25 11:23:46
NME

Base Information

Drug NameSKLB-646
Drug Alias NameSKLB-646
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitorsTyrosine-protein kinase SRC inhibitors +[4] 
TargetsSerine/threonine-protein kinase B-rafC-Raf kinaseTyrosine-protein kinase SRC +[4] 
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesWest China Hospital Of Sichuan University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWest China Hospital Of Sichuan University
Active IndicationsN/A
Inactive IndicationsTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A